Clinical Trial Update: Evaluation of Recombinant Humanized Anti-CD25 Monoclonal Antibody for Preventing Graft-versus-host Disease After Haploidentical/matched Unrelated Donor Hematopoietic Stem Cell Transplantation in Patients with Transfusion-dependent Thalassemia [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating a recombinant humanized anti-CD25 monoclonal antibody to prevent graft-versus-host disease after haploidentical or matched u…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transfusion-dependent Thalassemia

Drugs mentioned

• Recombinant Humanized Anti-CD25 Monoclonal Antibody

Snippet

Sponsor: Rongrong Liu | Conditions: Transfusion Dependent Thalassemia | Phase 2 | Status: RECRUITING